AI-guided INTENDD® drastically improves drug discovery productivity of hit identification to lead optimization by predicting the binding pose of small molecule to target protein and separating its activity into 8 classes of 3-digits pmol/L to 1-digit mmol/L orders.
Interprotein conducts the development of INTENDD-based AI drug discovery technology in collaboration with A.I. Squared, Inc., which has an excellent deep learning technology, and has established AI-guided INTENDD®, an activity prediction system for small molecules. The activity prediction by this system reaches a practical level with the highest accuracy all over the world and is expected to change the paradigm of current drug discovery processes. We are aiming at AI-based de novo drug design without dependence on compound libraries as a final goal.